Yd Bio(NASDAQ) YDES

Market Cap$250.78M

Since IPO (2020)-66%

5 Year-65%

1 Year-76%

1 Month+57%

$4.25

+20.06%

+0.71Today

Yd Bio last closing stock price
Metric	Price	Date
Last close	USD 3.54	2026-09-04

Yd Bio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-26.25%	USD 4.80	2026-08-28
1 month	+57.33%	USD 2.25	2026-08-05
3 month	+17.61%	USD 3.01	2026-06-05
Year to date	-70.96%	USD 12.19	2025-12-31
1 year	-75.97%	USD 14.73	2025-09-04
3 year	-68.81%	USD 11.35	2023-09-05
5 year	-64.92%	USD 10.09	2021-09-03
Since inception	-65.96%	USD 10.40	2020-12-23

Yd Bio Financials at a Glance

Market Cap

$250.78M

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.97M

EPS (TTM)

-$0.99

P/E Ratio

-3.58

Dividend

$0.00

Beta (Volatility)

0.08 (Low)

Dividend

$0.00

Beta (Volatility)

0.08 (Low)

Price

$4.25

Volume

503,295.806

Open

$3.72

Price

$4.25

Volume

503,295.806

Open

$3.72

Previous Close

$4.25

Daily Range

$3.65 - $4.50

52-Week Range

$1.70 - $25.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.08 (Low)

Price

$4.25

Volume

503,295.806

Open

$3.72

Previous Close

$4.25

Daily Range

$3.65 - $4.50

52-Week Range

$1.70 - $25.00

Estimated Earnings Date

N/A

YDES News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yd Bio

YD Bio Limited is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm focuses on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, aiming to revolutionize treatment options for diseases with significant unmet medical needs.

Products and Services

Medical diagnostics for cancer prevention
Exosome-based therapeutics
Innovative solutions for unmet medical needs

Growth Outlook

Market cap of approximately $281.9 million indicates strong investor interest
Recent quarterly net income shows potential for recovery
Focus on innovative therapies positions the company for future growth

Financial Highlights

Trailing twelve months (TTM) revenue of $0 reflects early-stage development
Recent quarterly net income of -$2.2 million shows ongoing investment in R&D
Current ratio of 5.88 indicates strong liquidity position

YD Bio Limited operates in the biotechnology sector, focusing on innovative solutions that address critical healthcare challenges. The company's commitment to developing advanced medical diagnostics and therapeutics positions it well within a growing market. Despite reporting no revenue in the trailing twelve months, the company is actively investing in research and development, as evidenced by its recent quarterly net income figures. The strong current ratio suggests that YD Bio Limited maintains a solid liquidity position, which is crucial for funding ongoing projects and navigating the challenges of clinical development. With a market cap of approximately $281.9 million, the company has garnered significant investor interest, reflecting confidence in its potential to deliver groundbreaking healthcare solutions.

AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ethan Shen, PhD, EMBA

Website

www.ydesgroup.com

Headquarters

Taipei, TP 115001, TW

YDES Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

52.09%

Return on Capital

N/A

Return on Assets

-40.51%

Earnings Yield

-27.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$250.78M

Shares Outstanding

70.84M

Volume

503.30K

Avg. Volume

182.31K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.38M

EBITDA

-$2.99M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$3.00

Free Cash Flow

-$1.18M

Cash & ST Invst.

$6.01M

Total Debt

$6.76K

Yd Bio Performance Analysis

Yd Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 510,360	N/A
2025	2025-12-31	USD 596,817	16.9%

Yd Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q1	2025-03-31	N/A
Q2	2025-06-30	N/A
Q4	2025-12-31	N/A

Yd Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.41	-31.5%
2023	2023-12-31	USD -0.58	N/A
2024	2024-12-31	USD -0.02	-96.2%
2025	2025-12-31	USD -0.12	471.6%

Yd Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	-81.5%
Q1	2025-03-31	-1080.0%
Q2	2025-06-30	33.7%
Q4	2025-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$250.78M

N/A

Market Cap/Employee

$16.72M

N/A

Employees

N/A

Net Income

-$2.21M

-112.9%

EBITDA

-$2.22M

-113.0%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$6.01M

+300380650.0%

Total Debt

$6.76K

N/A

Accounts Receivable

$712.26K

+1221.3%

Inventory

$1.88M

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$6.76K

N/A

Return on Assets

-40.51%

N/A

Return on Invested Capital

-6.12%

N/A

Free Cash Flow

-$298.19K

+49.7%

Operating Cash Flow

-$298.19K

+49.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LENZLENZ Therapeutics, Inc.

LENZLENZ Therapeutics, Inc.$5.33-10.57%

PRMEPrime Medicine, Inc.

PRMEPrime Medicine, Inc.$3.56-3.78%

TBPHTheravance Biopharma Inc

TBPHTheravance Biopharma Inc$17.06-0.12%

GERNGeron Corporation

GERNGeron Corporation$1.51-3.82%

BTXBlackRock Technology and Private Equity Term Trust

BTXBlackRock Technology and Private Equity Term Trust$9.01+0.78%

GLUEMonte Rosa Therapeutics, Inc.

GLUEMonte Rosa Therapeutics, Inc.$14.27+3.11%

TYRATyra Biosciences, Inc.

TYRATyra Biosciences, Inc.$26.73-6.70%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$104.47+0.09%

NVDANvidia

NVDANvidia$225.73-0.02%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.28-0.01%

NOKNokia

NOKNokia$10.65+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$153.47+0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.87+0.08%

NUNu Holdings

NUNu Holdings$15.33-0.00%

Questions About YDES

What is the current price of Yd Bio?

Yd Bio is trading at $4.25 per share.

What is the 52-week range for Yd Bio?

Over the past 52 weeks, Yd Bio has traded between $1.70 and $25.00.

How much debt does Yd Bio have?

As of the most recent reporting period, Yd Bio reported total debt of $0.00.

How much cash does Yd Bio have on hand?

Yd Bio reported $6.31K in cash and cash equivalents in its most recent financial results.

What is Yd Bio’s dividend yield?

Yd Bio does not currently have a dividend yield.

Yd Bio(NASDAQ) YDES

Yd Bio Financials at a Glance

YDES News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Yd Bio

YDES Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Yd Bio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About YDES

What is the current price of Yd Bio?

What is the 52-week range for Yd Bio?

How much debt does Yd Bio have?

How much cash does Yd Bio have on hand?

What is Yd Bio’s dividend yield?

Premium Investing Services